Piper Sandler rates Twist Bioscience 'Overweight' with $85 price target, signaling 25% upside potential.

Piper Sandler analyst David Westenberg initiated coverage on Twist Bioscience with an 'Overweight' rating and set a price target of $85, indicating a potential 25.42% upside from the current trading price of $67.77. Twist Bioscience operates in synthetic biology, focusing on synthetic DNA manufacturing in the growing genomics sector, which is benefiting from rising demand for precision medicine. The company's market cap is approximately $4.22 billion, and its stock has shown strong performance with a 52-week range between $23.30 and $80.50. This positive analyst outlook suggests confidence in Twist Bioscience's future growth prospects over the next 6 to 12 months.